Dynavax Technolo Stock Price, News & Analysis

Dynavax Technologies (Nasdaq: DVAX) announced it will report its fourth quarter and full year 2021 financial results on February 28, 2022, after market close. A conference call and live audio webcast will follow at 4:30 p.m. ET. The company focuses on developing innovative vaccines, including its approved hepatitis B vaccine, HEPLISAV-B. Dynavax is also advancing its CpG 1018 adjuvant for various infectious diseases and collaborating on vaccines for COVID-19 and other diseases.

Dynavax Technologies Corporation (Nasdaq: DVAX) announced on February 2, 2022, the granting of nonstatutory stock options for 105,000 shares and restricted stock units (RSUs) covering 73,250 shares to 11 new employees. The stock options were priced at $12.65 per share, aligning with the market close on the grant date. Each option has a seven-year term and a three-year vesting schedule. These grants comply with Nasdaq Listing Rule 5635(c)(4) and are part of the 2021 Inducement Award Plan, aimed at incentivizing new hires as the company advances its vaccine development initiatives.

Dynavax Technologies Corporation (Nasdaq: DVAX) outlined its strategic priorities for 2022 and introduced a new herpes zoster (shingles) vaccine candidate. Anticipating profitability, the company expects continued revenue growth from its HEPLISAV-B hepatitis B vaccine and CpG 1018 adjuvant supply for COVID-19 vaccines. The CDC's recent recommendations for HEPLISAV-B could expand its market opportunity to $800 million by 2027. Additionally, the global clinical trial for the shingles vaccine aims to demonstrate safety and immunogenicity, with results expected by the end of 2022.

Dynavax Technologies Corporation (Nasdaq: DVAX) announced the grant of nonstatutory stock options for 94,000 shares and restricted stock units (RSUs) for 2,500 shares to 5 newly-hired employees. The stock options were awarded on January 4, 2022, at an exercise price of $13.40, matching the closing stock price on that date. The stock options have a 7-year term and follow a vesting schedule of one-third after one year and the remainder monthly over two years. The RSUs will vest one-third annually. These grants were made to comply with Nasdaq Listing Rule 5635(c)(4).

Dynavax Technologies (Nasdaq: DVAX) has announced that CEO Ryan Spencer will present at the H.C. Wainwright Virtual BioConnect 2022 Conference scheduled for January 10-13, 2022. The on-demand presentation will be accessible starting January 10, 2022, at 7:00 a.m. E.T. on the company’s website under the 'Events & Presentations' section. Dynavax is a biopharmaceutical firm specializing in developing vaccines, including HEPLISAV-B®, which is approved for preventing hepatitis B infections in adults.

Dynavax Technologies Corporation (DVAX) announced that Biological E's COVID-19 vaccine, CORBEVAX™, received emergency use approval from India's Drugs Controller General. This vaccine uses Dynavax's CpG 1018® adjuvant. The companies have a commercial supply agreement for 300 million doses, bolstering Dynavax's supply capabilities for 2022 and beyond. The CpG 1018 adjuvant is proven to enhance vaccine immune response and is included in multiple vaccines, contributing over $197 million in revenue in 2021.

Sensorion (Euronext Paris: ALSEN) has appointed Scott D. Myers as Chairman of its Board of Directors, succeeding Edwin Moses who is stepping down on December 19. Myers, currently Chairman at Dynavax Technologies (NASDAQ: DVAX) and Harpoon Therapeutics (NASDAQ: HARP), brings nearly 30 years of experience in the pharmaceutical sector. His leadership is expected to enhance Sensorion's clinical development and international presence, particularly as the company focuses on its innovative therapies for hearing loss disorders.

Dynavax Technologies Corporation (Nasdaq: DVAX) has appointed Elaine Sun to its Board of Directors. Ms. Sun, who brings over 20 years of experience in life sciences and investment banking, has previously held significant roles at Halozyme and SutroVax. CEO Ryan Spencer expressed confidence in her expertise to enhance Dynavax's strategic direction, particularly in expanding HEPLISAV-B market share and advancing their CpG 1018 adjuvant development. The announcement highlights Dynavax's commitment to innovative vaccine solutions against infectious diseases.

Dynavax Technologies Corporation (Nasdaq: DVAX) announced the grant of nonstatutory stock options for 58,500 shares to 5 new employees on December 1, 2021. The options have an exercise price of $15.11 per share, aligning with the closing stock price on that date. Each option has a 7-year term and will vest over three years. This grant complies with Nasdaq Listing Rule 5635(c)(4) as an inducement to employment under the 2021 Inducement Award Plan.